REUN — Reunion Neuroscience Share Price
Last trade - 00:00- $12.47m
- -$7.91m
- 10
- 41
- 28
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.81 | ||
| Price to Tang. Book | 0.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -160.96% | ||
| Return on Equity | -86.35% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | 0.96 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.
Directors
- Ronan Levy CHM
- Hannan Fleiman PRE
- Joseph del Moral CEO
- Donna Wong CFO (54)
- Mujeeb Jafferi COO
- Ben Medrano SVP
- Amardeep Manhas CTO (37)
- Nathan Bryson CSO (57)
- Paula Hewitt VPR (48)
- Tyler Dyck TRS (30)
- Ryan Yermus OTH
- Barry Fishman LED (62)
- Helen Boudreau IND (55)
- Ellen Lubman IND (45)
- Dieter Weinand IND (61)
- Last Annual
- March 31st, 2023
- Last Interim
- March 31st, 2023
- Incorporated
- October 1st, 2020
- Public Since
- February 18th, 2009
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 11,717,616
- Address
- 30 Duncan Street, Suite 401, TORONTO, M5V 2C3
- Web
- https://www.meetfieldtrip.com/
- Phone
- Auditors
- Ernst & Young LLP
Upcoming Events for REUN
Similar to REUN
Abcam
NASDAQ Global Select Market
Acelyrin
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 01:19 UTC, shares in Reunion Neuroscience are trading at $1.12. This share price information is delayed by 15 minutes.
Shares in Reunion Neuroscience last closed at $1.12 and the price had moved by -74.1% over the past 365 days. In terms of relative price strength the Reunion Neuroscience share price has underperformed the S&P500 Index by -77.77% over the past year.
The overall consensus recommendation for Reunion Neuroscience is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreReunion Neuroscience does not currently pay a dividend.
Reunion Neuroscience does not currently pay a dividend.
Reunion Neuroscience does not currently pay a dividend.
To buy shares in Reunion Neuroscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.12, shares in Reunion Neuroscience had a market capitalisation of $13.04m.
Here are the trading details for Reunion Neuroscience:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: REUN
Based on an overall assessment of its quality, value and momentum Reunion Neuroscience is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Reunion Neuroscience is $0.76. That is 32.4% below the last closing price of $1.12.
Analysts covering Reunion Neuroscience currently have a consensus Earnings Per Share (EPS) forecast of -CA$1.62 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Reunion Neuroscience. Over the past six months, its share price has underperformed the S&P500 Index by -27.67%.
As of the last closing price of $1.12, shares in Reunion Neuroscience were trading -1.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Reunion Neuroscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Reunion Neuroscience's management team is headed by:
- Ronan Levy - CHM
- Hannan Fleiman - PRE
- Joseph del Moral - CEO
- Donna Wong - CFO
- Mujeeb Jafferi - COO
- Ben Medrano - SVP
- Amardeep Manhas - CTO
- Nathan Bryson - CSO
- Paula Hewitt - VPR
- Tyler Dyck - TRS
- Ryan Yermus - OTH
- Barry Fishman - LED
- Helen Boudreau - IND
- Ellen Lubman - IND
- Dieter Weinand - IND